JUNIOR STRENGTH IBUPROFEN Drug Patent Profile
✉ Email this page to a colleague
When do Junior Strength Ibuprofen patents expire, and what generic alternatives are available?
Junior Strength Ibuprofen is a drug marketed by L Perrigo Co and is included in one NDA.
The generic ingredient in JUNIOR STRENGTH IBUPROFEN is ibuprofen. There are sixty-four drug master file entries for this compound. Two hundred and thirty-three suppliers are listed for this compound. Additional details are available on the ibuprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Junior Strength Ibuprofen
A generic version of JUNIOR STRENGTH IBUPROFEN was approved as ibuprofen by STRIDES PHARMA on September 24th, 1986.
Summary for JUNIOR STRENGTH IBUPROFEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 207 |
Clinical Trials: | 1 |
Patent Applications: | 4,294 |
Formulation / Manufacturing: | see details |
DailyMed Link: | JUNIOR STRENGTH IBUPROFEN at DailyMed |
Recent Clinical Trials for JUNIOR STRENGTH IBUPROFEN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Reckitt Benckiser Healthcare (UK) Limited | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for JUNIOR STRENGTH IBUPROFEN
US Patents and Regulatory Information for JUNIOR STRENGTH IBUPROFEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
L Perrigo Co | JUNIOR STRENGTH IBUPROFEN | ibuprofen | TABLET;ORAL | 075367-001 | Apr 22, 1999 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for JUNIOR STRENGTH IBUPROFEN
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Recordati Rare Diseases | Pedea | ibuprofen | EMEA/H/C/000549 Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. |
Authorised | no | no | no | 2004-07-28 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |